MEP13308A - 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation - Google Patents
1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activationInfo
- Publication number
- MEP13308A MEP13308A MEP-133/08A MEP13308A MEP13308A ME P13308 A MEP13308 A ME P13308A ME P13308 A MEP13308 A ME P13308A ME P13308 A MEP13308 A ME P13308A
- Authority
- ME
- Montenegro
- Prior art keywords
- microglia activation
- illnesses associated
- benzimidazoles
- treating illnesses
- diaryl
- Prior art date
Links
- 230000004913 activation Effects 0.000 title abstract 2
- 210000000274 microglia Anatomy 0.000 title abstract 2
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 2
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Opisuje se benzimidazoli opšte formule (I) i primjena benzimidazol derivata za proizvodnju ljekova za liječenje i profi lisku oboljenja koja su povezana sa akti viranjem mikroglija.Benzimidazoles of general formula (I) and the use of benzimidazole derivatives for the manufacture of medicaments for the treatment and prophylaxis of diseases associated with the activation of microglia are described.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10002898 | 2000-01-14 | ||
PCT/EP2001/000334 WO2001051473A1 (en) | 2000-01-14 | 2001-01-12 | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
Publications (1)
Publication Number | Publication Date |
---|---|
MEP13308A true MEP13308A (en) | 2010-10-10 |
Family
ID=7628535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-133/08A MEP13308A (en) | 2000-01-14 | 2001-01-12 | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP1246808B1 (en) |
JP (1) | JP2003523961A (en) |
KR (1) | KR100703908B1 (en) |
CN (1) | CN1301975C (en) |
AT (1) | ATE520669T1 (en) |
AU (1) | AU782993B2 (en) |
BG (1) | BG65858B1 (en) |
BR (1) | BR0107628A (en) |
CA (1) | CA2396227C (en) |
CY (1) | CY1112962T1 (en) |
CZ (1) | CZ303726B6 (en) |
DK (1) | DK1246808T3 (en) |
EA (1) | EA006302B1 (en) |
EE (1) | EE05515B1 (en) |
ES (1) | ES2372026T3 (en) |
HR (1) | HRP20020664B1 (en) |
HU (1) | HU228366B1 (en) |
IL (2) | IL150150A0 (en) |
ME (1) | MEP13308A (en) |
MX (1) | MXPA02005742A (en) |
NO (1) | NO326408B1 (en) |
NZ (1) | NZ519326A (en) |
PL (1) | PL209573B1 (en) |
PT (1) | PT1246808E (en) |
RS (1) | RS51860B (en) |
SI (1) | SI1246808T1 (en) |
SK (1) | SK287527B6 (en) |
TW (1) | TWI287005B (en) |
UA (1) | UA75589C2 (en) |
WO (1) | WO2001051473A1 (en) |
ZA (1) | ZA200206470B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
DE10134775A1 (en) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-alkyl-2.aryl-benzimidazole derivatives, their use for the manufacture of medicaments and pharmaceutical preparations containing these derivatives |
DE10135050A1 (en) * | 2001-07-09 | 2003-02-06 | Schering Ag | 1-Ary1-2-N-, S- or O-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing them |
US6903126B2 (en) | 2001-07-09 | 2005-06-07 | Schering Ag | 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
DE10207844A1 (en) | 2002-02-15 | 2003-09-04 | Schering Ag | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the preparation of medicaments and pharmaceutical preparations containing these derivatives |
DE10207843A1 (en) * | 2002-02-15 | 2003-09-04 | Schering Ag | Microlia inhibitors for interruption of interleukin 12 and IFN-gamma mediated immune responses |
US6962932B2 (en) | 2002-02-15 | 2005-11-08 | Schering Aktiengesellschaft | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
EP1608628A2 (en) * | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
SE0302570D0 (en) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0302573D0 (en) * | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
MX2007003105A (en) | 2004-09-24 | 2007-06-07 | Aztrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof i. |
TW200745049A (en) | 2006-03-23 | 2007-12-16 | Astrazeneca Ab | New crystalline forms |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
JP5255994B2 (en) * | 2008-11-04 | 2013-08-07 | 国立大学法人 岡山大学 | Nuclear receptor ligand |
WO2012012478A1 (en) * | 2010-07-21 | 2012-01-26 | Merck Sharp & Dohme Corp. | Aldosterone synthase inhibitors |
CN102382102B (en) * | 2010-09-06 | 2014-01-08 | 中国科学院广州生物医药与健康研究院 | Amide compound |
JP6200903B2 (en) * | 2012-02-17 | 2017-09-20 | キネタ フォー エルエルシー | Antiviral drugs for the treatment of arenavirus infections |
WO2014044611A1 (en) | 2012-09-20 | 2014-03-27 | Bayer Pharma Aktiengesellschaft | 1-aryl-2-heteroaryl benzimidazoles for the induction of neuronal regeneration |
PL3390367T3 (en) * | 2015-12-15 | 2021-03-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
BR112021006488A2 (en) | 2018-10-05 | 2021-07-06 | Annapurna Bio Inc | compounds and compositions for the treatment of conditions associated with apj receptor activity |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4430502A (en) * | 1982-08-13 | 1984-02-07 | The Upjohn Company | Pyridinyl substituted benzimidazoles and quinoxalines |
DK0520200T3 (en) * | 1991-06-24 | 1998-09-23 | Neurosearch As | Imadazole compounds, their preparation and use |
MX9203323A (en) * | 1991-07-11 | 1994-07-29 | Hoechst Ag | THE USE OF XANTHINE DERIVATIVES FOR THE TREATMENT OF SECONDARY INJURIES OF THE NERVOUS CELLS AND FUNCTIONAL DISORDERS AFTER CRANIAL-BRAIN TRAUMA. |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
DE4330959A1 (en) * | 1993-09-09 | 1995-03-16 | Schering Ag | New benzimidazole derivatives, processes for their preparation and their pharmaceutical use |
US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
NZ270985A (en) * | 1994-04-29 | 1997-06-24 | Lilly Co Eli | Substituted benzimidazole derivatives; medicaments and preparation of medicaments |
WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
JP2000506529A (en) * | 1996-03-11 | 2000-05-30 | イーライ・リリー・アンド・カンパニー | Methods for treating or preventing interstitial cystitis |
-
2001
- 2001-01-12 EE EEP200200390A patent/EE05515B1/en not_active IP Right Cessation
- 2001-01-12 EP EP01915133A patent/EP1246808B1/en not_active Expired - Lifetime
- 2001-01-12 CN CNB018037666A patent/CN1301975C/en not_active Expired - Fee Related
- 2001-01-12 AU AU42332/01A patent/AU782993B2/en not_active Ceased
- 2001-01-12 KR KR1020027009085A patent/KR100703908B1/en not_active IP Right Cessation
- 2001-01-12 CZ CZ20022420A patent/CZ303726B6/en not_active IP Right Cessation
- 2001-01-12 IL IL15015001A patent/IL150150A0/en unknown
- 2001-01-12 WO PCT/EP2001/000334 patent/WO2001051473A1/en active IP Right Grant
- 2001-01-12 MX MXPA02005742A patent/MXPA02005742A/en active IP Right Grant
- 2001-01-12 NZ NZ519326A patent/NZ519326A/en not_active IP Right Cessation
- 2001-01-12 AT AT01915133T patent/ATE520669T1/en active
- 2001-01-12 EA EA200200742A patent/EA006302B1/en not_active IP Right Cessation
- 2001-01-12 PL PL356091A patent/PL209573B1/en unknown
- 2001-01-12 CA CA2396227A patent/CA2396227C/en not_active Expired - Fee Related
- 2001-01-12 ES ES01915133T patent/ES2372026T3/en not_active Expired - Lifetime
- 2001-01-12 ME MEP-133/08A patent/MEP13308A/en unknown
- 2001-01-12 DK DK01915133.1T patent/DK1246808T3/en active
- 2001-01-12 PT PT01915133T patent/PT1246808E/en unknown
- 2001-01-12 SK SK1000-2002A patent/SK287527B6/en not_active IP Right Cessation
- 2001-01-12 JP JP2001551855A patent/JP2003523961A/en active Pending
- 2001-01-12 RS YU45702A patent/RS51860B/en unknown
- 2001-01-12 BR BR0107628-0A patent/BR0107628A/en not_active IP Right Cessation
- 2001-01-12 SI SI200131004T patent/SI1246808T1/en unknown
- 2001-01-12 TW TW090100751A patent/TWI287005B/en not_active IP Right Cessation
- 2001-01-12 HU HU0204011A patent/HU228366B1/en not_active IP Right Cessation
- 2001-12-01 UA UA2002086720A patent/UA75589C2/en unknown
-
2002
- 2002-06-11 IL IL150150A patent/IL150150A/en not_active IP Right Cessation
- 2002-06-13 BG BG106821A patent/BG65858B1/en unknown
- 2002-07-12 NO NO20023362A patent/NO326408B1/en not_active IP Right Cessation
- 2002-08-13 ZA ZA200206470A patent/ZA200206470B/en unknown
- 2002-08-13 HR HR20020664A patent/HRP20020664B1/en not_active IP Right Cessation
-
2011
- 2011-11-16 CY CY20111101101T patent/CY1112962T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MEP13308A (en) | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation | |
FR18C1012I2 (en) | STAUROSPORINE DERIVATIVES INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY | |
ATE301651T1 (en) | SUBSTITUTED BENZIMIDAZOLES | |
MX2007003332A (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors. | |
PT1119543E (en) | N-ARALHYLAMINOTETRALINES AS LIGANDS FOR NEUROPEPTIDE AND Y5 RECEPTOR | |
DE60115466D1 (en) | ACTIVE PROCESSORS OF IMIDAZOPYRIDINE DERIVATIVES | |
TR199500956A2 (en) | Benzimidazole derivatives. | |
TR199701536T1 (en) | Use of benzimidazoles in the manufacture of a drug for the treatment of leukemia. | |
NO20013414D0 (en) | New use of melagatran | |
DE60128100D1 (en) | ANALGICAL DRUG | |
SE0004101D0 (en) | New use | |
TR200302134T4 (en) | Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid and / or physiologically acceptable salts thereof as anti-cancer agents. | |
NO20032006D0 (en) | Use of melagatran for the manufacture of a medicament for the treatment of ischemic disorders | |
PT1404656E (en) | BENZIMIDAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE ACTIVATION OF MICROGLIA AS INFLAMMATORY, ALLERGIC, INFECTIOUS OR AUTOIMUNE DISEASES | |
PE20010621A1 (en) | SUBSTITUTE BENZIMIDAZOLE DERIVATIVES, PROCEDURE FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | |
PT1220844E (en) | BENZIMIDAZOLE DERIVATIVES SUBSTITUTED AS ARILSSULFONAMIDE AND ITS USE AS TRIPTASE INHIBITORS | |
EE04641B1 (en) | Benzimidazoles and benzoxazoles, their use in the manufacture of medicaments for the treatment of respiratory and dermatoses, and medicaments containing them |